Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 33 min 19 sec ago

Kalytera to Enter Medical Cannabis Market With Focus on Treatment of Psoriasis and Menstrual Cramps

Thu, 19/07/2018 - 08:00
SAN FRANCISCO & TEL AVIV, ISRAEL--(BUSINESS WIRE)--Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has entered into an agreement with Beetlebung Pharma, Ltd. ("BPL") for an option to acquire all rights to medical cannabis products in development by BPL for the treatment of both dermatologic diseases and women's health. Under this agreement, Kalytera will have the option to license from BPL certain proprietary medical cannabi

Turnstone Biologics Announces Key Appointments to Senior Leadership Team

Thu, 19/07/2018 - 08:00
OTTAWA, Ontario & NEW YORK--(BUSINESS WIRE)--Turnstone Biologics, a clinical-stage immuno-oncology company developing the next generation of oncolytic viral therapies, today announced the appointment of Jane Pritchett Henderson as Chief Financial Officer. Ms. Henderson brings nearly 30 years of experience as a health care investment banker and financial leader at several biotechnology companies, most recently as the CFO and SVP of Corporate Development of Voyager Therapeutics. In addition, Turn

World Renowned Academic Medical Center Acquires Synaptive's Next-Generation Robotic System for Minimally Invasive Neurosurgery

Tue, 17/07/2018 - 10:00
TORONTO--(BUSINESS WIRE)--#cdntech--Synaptive Medical Inc. today announced that Duke University Medical Center has acquired its connected neurosurgery system.

New Xytex Location in Athens, Georgia

Mon, 16/07/2018 - 17:00
ATLANTA--(BUSINESS WIRE)--Xytex Cryo International has opened a new office located in Athens, Georgia.

Fusion Pharma Announces Formation of Advisory Board

Mon, 16/07/2018 - 09:00
BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharma Announces Formation of Advisory Board

Bioasis Announces Non-Brokered Private Placement

Mon, 16/07/2018 - 09:00
RICHMOND, British Columbia & GUILFORD, Conn.--(BUSINESS WIRE)--$BIOAF #BBB--Bioasis today announced the Company intends to pursue a non-brokered private placement.

Gilead Receives Approval in Canada for BIKTARVY™ (bictegravir, emtricitabine, tenofovir alafenamide) for the Treatment of HIV-1 Infection

Thu, 12/07/2018 - 08:00
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for Biktarvy™ (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. BIKTARVY combines the potency of a novel integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (F

Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

Wed, 11/07/2018 - 17:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES). VOS, which is a proprietary nanomicellar formulation, enables high concentrations of voclosporin to be incorporated into a clear aqueous, preservative-free solution for l

Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic

Wed, 11/07/2018 - 09:00
RICHMOND, British Columbia & GUILFORD, Conn. & DURHAM, N.C.--(BUSINESS WIRE)--$BIOAF #BBB--Bioasis & BioAgilytix announce partnership to advance the xB3-001 program to IND submission and into the clinic.

Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant

Wed, 11/07/2018 - 09:00
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the randomized, Phase 3 TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral NINLARO® (ixazomib) as a maintenance therapy resulted in a statistically significant improvement in progression-free survival (PFS) versus placebo. The trial evaluated the effect of NINLARO as a maintenance therapy in adult patients diagnosed with multiple myeloma who respon

Visura Technologies Receives FDA Clearance for the TEE Camera Assist Device System

Tue, 10/07/2018 - 11:00
EVANSTON, Ill.--(BUSINESS WIRE)--#FDAClearance--Visura Technologies, a start-up medical device company based in Evanston, IL, has received 510(k) clearance from the US Food and Drug Administration.

Antibe Completes Share Issuance in Connection with Citagenix Credit Facility

Fri, 06/07/2018 - 20:00
TORONTO--(BUSINESS WIRE)--Antibe Completes Share Issuance in Connection with Citagenix Credit Facility

Sproutly Canada Inc. Announces Completion of Reverse Takeover Transaction and Conditional Approval to Commence Trading on July 9, 2018

Fri, 06/07/2018 - 15:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sproutly Canada, Inc. (formerly Stone Ridge Exploration Corp.) (“Sproutly Canada" or the “Company”) is pleased to announce that it has closed the previously announced proposed plan of arrangement under the Canada Business Corporations Act (the “Arrangement”) pursuant to which, among other things, Sproutly, Inc. ("Sproutly") completed a reverse takeover of Stone Ridge Exploration Corp. (“Stone Ridge”). Immediately prior to the completion of the Arran

Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy

Fri, 06/07/2018 - 10:00
TIVERTON, Canada & GARCHING, Germany--(BUSINESS WIRE)--#NETcancer--Bruce Power and ITM Isotopen Technologien München have signed an agreement to explore the production of the medical radioisotope n.c.a. Lutetium-177.

Canada's Biotechnology Industry - Porter's Five Forces Strategy Analysis, Along With a Brief Overview of the Market - ResearchAndMarkets.com

Fri, 06/07/2018 - 09:00
DUBLIN--(BUSINESS WIRE)--The "Canada s Biotechnology Industry - Porter s Five Forces Strategy Analysis" report has been added to ResearchAndMarkets.com's offering. The publisher analyzes the Canadian Biotechnology industry in the Michael Porter's Five Forces Analysis. It uses concepts developed in Industrial Organization (IO) economics to derive five forces that determine the competitive intensity and therefore attractiveness of a market. Porter referred to these forces as the microenvironment,

Global Strategic Business Outlook on the Bioinformatics Market (2015-2018 to 2022): Next Generation Sequencing Drives Demand for Bioinformatics - ResearchAndMarkets.com

Wed, 04/07/2018 - 14:00
DUBLIN--(BUSINESS WIRE)--The "Bioinformatics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets in US$ by the following Segments: S

Ag-West Bio Welcomes New Members to the Board of Directors

Tue, 03/07/2018 - 10:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Ag-West Bio is pleased to announce the appointment of three new members to the board of directors at the annual meeting on June 18, 2018. The new directors are: Rick Green (Vice-President, Technology, POS Bio-Sciences); Leah Olson (President, Agricultural Manufacturers of Canada); and Lee Whittington (former President and CEO, Prairie Swine Centre). Ag-West Bio’s board of directors comprises top-calibre individuals from a wide range of backgrounds. Wilf

DiaCarta Inc. Appoints Arrow Diagnostics as Exclusive Distributor for ColoScape™ in Italy

Mon, 02/07/2018 - 09:00
RICHMOND, Calif. & GENOA, Italy--(BUSINESS WIRE)--DiaCarta Inc. announced that it has signed a distribution agreement with Arrow Diagnostics.

Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results

Fri, 29/06/2018 - 19:00
TORONTO--(BUSINESS WIRE)--ANTIBE THERAPEUTICS REPORTS 2018 YEAR-END FINANCIAL AND OPERATING RESULTS

MEDISCA Signs Exclusive Distribution Agreement for FLAVORx Flavours in the Canadian Market

Fri, 29/06/2018 - 16:00
MONTREAL--(BUSINESS WIRE)--#Compounding--MEDISCA, the industry leader in providing high quality compounding solutions and services to pharmacists worldwide, proudly announced today that through its collaboration with FLAVORx, it will now provide this exclusive product offering to the Canadian market. This agreement is based on a successful three-year collaboration with FLAVORx in the United States, for which MEDISCA holds exclusive distribution rights for the pharmaceutical compounding industry. “Patients, w

Pages